Novozymes Biopharma supplies Neomend with albucult for use in ...

novozymes.com

Novozymes Biopharma supplies Neomend with albucult for use in ...

Novozymes Biopharmasupplies Neomend withalbucult ® for use in uniquesealant technologyNOTTINGHAM, UK – February 10, 2010 – Novozymes Biopharma,part of Novozymes A/S world leader in bioinnovation, is pleased toannounce that its recombinant human albumin, albucult ® , is being usedby Neomend in its ProGEL ® PLATINUM surgical sealant. This product willbe commercially available in Europe beginning in the second quarter of2011. Neomend is an innovator in sealant and adhesion preventionproducts for the surgical marketplace. The company utilizes albucult asa key component in ProGEL PLATINUM, the only sealant of its kinddeveloped to treat pleural air leaks following lung resection surgery.Neomend’s ProGEL is a hydrogel polymer consisting of Novozymesalbucult and a cross-linking component of polyethylene glycol (PEG).When they are combined, a rapid cross-linking reaction creates ahydrogel matrix that results in the formation of a strong, adherent andflexible seal. The technology, which has received a European CE Mark,enables surgeons to more effectively treat lung air leaks during surgeryand has already been used in more than 8,000 procedures in the U.Ssince April of last year.David Renzi, Neomend’s President and CEO, comments: “Novozymes’extensive experience in manufacturing, regulatory and global supply,combined with its commitment to innovation, makes the company theideal partner for Neomend to work with on its unique sealanttechnology. We will launch ProGEL PLATINUM in Europe in the secondquarter of this year, while also continuing the development of thisplatform technology into other clinical areas such as spine, generalsurgery and gynecology.”Page 1 of 3Novozymes · Krogshoejvej 36 · 2880 Bagsvaerd · Denmark · Tel. +45 4446 0000 · www.novozymes.com


Novozymes is delighted that Neomend has selected albucult for use inits unique sealant technology”, says Dermot Pearson, MarketingDirector, Novozymes Biopharma. “The partnership demonstratesNovozymes’ commitment to providing quality materials for use in thehealthcare, pharmaceutical and biotechnology industries and allows thecompany to position itself as a reliable partner in the wound sealant andmedical device markets.”The use of albucult in ProGEL PLATINUM and other medical devicesconfers a range of unique advantages not possible with animal-derivedingredients such as sustainability of supply, GMP compliance andimproved biocompatibility. Albucult also delivers unprecedentedperformance and quality benefits to medical applications includingsealants, device coating and cell therapy applications while ensuringbatch-to-batch consistency which can significantly reduce lot testingburdens for customers.For further information on Novozymes products, please visitwww.biopharma.novozymes.com###About Neomend, Inc.Neomend, based in Irvine, California, is a private company focused on the design,development and commercialization of surgical sealants and adhesion prevention productsderived from the ProGEL technology platform. The company has a direct sales force of 30people in the U.S. and holds 28 issued U.S. patents in chemical composition and deliveryapplicators. For more information, visit www.Neomend.com or call 949-916-1630.About NovozymesNovozymes is the world leader in bioinnovation. Together with customers across a broadarray of industries, we create tomorrow’s industrial biosolutions, improving our customers'business and the use of our planet's resources.With over 700 products used in 130 countries, Novozymes’ bioinnovations improveindustrial performance and safeguard the world’s resources by offering superior andsustainable solutions for tomorrow’s ever-changing marketplace. Read more atwww.novozymes.com.Contact:Novozymes Biopharma:Sally Vernon, Customer Communications ManagerSYKE@novozymes.comTel. +44 115 955 3355Page 2 of 3Novozymes · Krogshoejvej 36 · 2880 Bagsvaerd · Denmark · Tel. +45 4446 0000 · www.novozymes.com


MEDIA CONTACTSEuropeAnnegrethe Møller JakobsenOffice: +45 4446 3050Mobile: +45 3077 3050agmj@novozymes.comChinaZhu XiaoqingOffice: +86 106 2987888+362Mobile: +86 138 012 40590xqzh@novozymes.comUSPaige DonnellyOffice: +1 919 494 3209Mobile: +1 919 218 4501pagd@novozymes.comBrazilSaionara Ribeiro de PaulaOffice: +55 41 3641 1112Mobile: +55 41 9971 7225saio@novozymes.comINVESTOR CONTACTSEuropeTobias BjorklundOffice: +45 4446 8682Mobile: +45 3077 8682tobb@novozymes.comUSThomas Steenbech BomhoffMobile: +1 919 649 2565tsbm@novozymes.comPage 3 of 3Novozymes · Krogshoejvej 36 · 2880 Bagsvaerd · Denmark · Tel. +45 4446 0000 · www.novozymes.com